Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2553-2561

  Hochster, Howard ^a   Wadler, Scott ^a   Runowicz, Carolyn ^a   Liebes, Leonard ^a   Cohen, Henry ^a   Wallach, Robert ^a   Sorich, Joan ^a   Taubes, Beth ^a   Speyer, James ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032795911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2553     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Young RC, Hubbard SP, De Vita VT: The chemotherapy of ovarian cancer. Cancer Treat Rep 1:99-110, 1974
3. Ozols RF, Schwartz PE, Eifel PJ: Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 3). Philadelphia, PA, Lippincott-Raven, 1997, pp 1502-1539
4. McGuire WP, Hoskins WG, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin: Patients with stage III and IV ovarian cancer. N Engl J Med 334:1-6, 1996
5. Piccart MJ, Bertelsen K, Stuart G, et al: Is cisplatin-paclitaxel the standard in first-line treatment of advance ovarian cancer? The EORTC GCCG NOCOVA, NCI-C, and Scottish intergroup experience. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1258)
6. Hsiang YH, Hertzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
7. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 49:5077-5082, 1988
8. Wang JC: DNA topoisomerases. Annu Rev Biochem 54:665-697, 1985
9. Potmesil M, Giovanella BC, Liu LF, et al: Pre-clinical studies of DNA topoisomerase-I targeted 9-amino and 10,11 methylenedioxy camptothecins, in Potmesil M, Kohn K, (eds): DNA Topoisomerases in Cancer. Oxford, UK, Oxford University Press, 1990, pp 299-311
10. Liu L: Anticancer drugs which convert DNA topoisomerases into DNA damaging agents, in: DNA Topology and Its Biological Effects. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1990, pp 371-389
11. Giovanella B, Stehlin J, Wall M, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
12. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
13. Hochster H, Liebes L, Speyer J, et al: Effect of prolonged topotecan infusion on topoisomerase I Levels: A phase I and pharmacodynamic study. Clin Cancer Res 3:1245-1252, 1997
14. Liebes L, Potmesil M, Kim T: Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 4:545-557, 1998
15. Boyum A: Isolation of mononuclear cells and granulocytes from human blood: Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation sedimentation at 1 g. Scand J Clin Lab Invest 97:77-89, 1968
16. Liebes L, Walsh CM, Chachoua A, et al: Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma. J Natl Cancer Inst 84:694-699, 1992
17. Beijnen J, Smith BR, Keijer WJ, et al: High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal 8:789-794, 1990
18. Burton K: Determination of DNA concentration with diphenylamine. Methods Enzymol 12:163-167, 1967
19. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC: High titers of autoantibodies to topoisomerase-1 (Scl-70) in sera from scleroderma patients. Science 231:737-740, 1986
20. Liu LF, Miller KG: Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78:3487-3491, 1981
21. Kaplan EL, Meier P: Non-parametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
22. Creemers GJ, Bolis G, Gore M, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 14:3056-3061, 1996
23. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
24. Johnson S, Pyle L, King K, Gore M: A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma. Eur J Cancer 58, 1997 (abstr 537)